Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Astellas PharmaALPMF 73 EV-to-EBIT is 10.02 as of Jul. 22, 2026, which is 30% below its 10-year median of 14.39. GuruFocus rates ALPMF with a GF Score™ of 73/100 and a GF Value™ of $14.19 (Fairly Valued). The stock has 4 warning signs investors should review. Among 689 Drug Manufacturers companies, Astellas Pharma ranks better than 67.78% on this metric.
This is a more accurate valuation of companies' operation because it considers the debt and cash on its balance sheet, and non-operating items such as interest payment, tax, and one-time items are not included in the Operating Income.
Astellas Pharma's Enterprise Value for the quarter that ended in Mar. 2026 was $30,676 Mil.
Astellas Pharma's EBIT for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $2,586 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Astellas Pharma EV-to-EBIT Related Terms
Astellas Pharma EV-to-EBIT Historical Data
* Premium members only.
The historical data trend for Astellas Pharma's EV-to-EBIT can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Drug Manufacturers - General subindustry, Astellas Pharma's EV-to-EBIT, along with its competitors' market caps and EV-to-EBIT data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Astellas Pharma EV-to-EBIT vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Astellas Pharma's EV-to-EBIT distribution charts can be found below:
* The bar in red indicates where Astellas Pharma's EV-to-EBIT falls into.
Astellas Pharma's current Enterprise Value is $25,919 Mil.
Astellas Pharma's EBIT for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $2,586 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Astellas Pharma (ALPMF) has a EV-to-EBIT of 10.02 as of Jul. 22, 2026. EV to EBIT ratio is the inverse of Joel Greenblatt's earnings yield definition. View historical data on Astellas Pharma and its competitors. This is 30% below median its historical median of 14.39. According to the industry distribution chart, Astellas Pharma ranks #222 out of 689 companies in the Drug Manufacturers industry, placing it in the top 32.2%.
Is Astellas Pharma's EV-to-EBIT too high?
Astellas Pharma's current EV-to-EBIT of 10.02 is 30% below median its 10-year median of 14.39. The Drug Manufacturers industry median EV-to-EBIT is 15.95. Astellas Pharma's value of 10.02 is 37.2% below this industry median. Based on the distribution chart, Astellas Pharma ranks #222 out of 689 companies in the Drug Manufacturers industry, which is above the industry midpoint. Overall, Astellas Pharma has a GF Score™ of 73/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does Astellas Pharma's EV-to-EBIT compare to LLY and JNJ?
According to the Drug Manufacturers industry distribution chart, Astellas Pharma ranks #222 out of 689 companies for EV-to-EBIT. This puts Astellas Pharma in the upper half of its industry. The industry median EV-to-EBIT is 15.95. Astellas Pharma's value of 10.02 is 37.2% below this benchmark. While the company's 10-year median is 14.39 vs. the industry median of 15.95, Astellas Pharma has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EV-to-EBIT for a Drug Manufacturers company?
The median EV-to-EBIT among Drug Manufacturers companies is 15.95, based on 689 companies in the industry. Companies in the top quartile (top 25%) have a EV-to-EBIT significantly above this median, while those in the bottom quartile fall well below. However, EV-to-EBIT should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Astellas Pharma's current EV-to-EBIT of 10.02 is 37.2% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EV-to-EBIT mean?
A high EV-to-EBIT can signal that a stock is expensive relative to its fundamentals. EV to EBIT ratio is the inverse of Joel Greenblatt's earnings yield definition. View historical data on Astellas Pharma and its competitors. For the Drug Manufacturers industry, the median EV-to-EBIT is 15.95 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Astellas Pharma's current EV-to-EBIT is 10.02, which is 30% below median its own 10-year median of 14.39. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Astellas Pharma stock overvalued right now?
Based on GuruFocus' analysis, Astellas Pharma (ALPMF) is currently considered Fairly Valued. The stock's GF Value™ is $14.19, compared to a current price of $12.85 — trading 9.4% below its estimated fair value. The current EV-to-EBIT is 10.02, which is 30% below median its 10-year median of 14.39 and 37.2% below the Drug Manufacturers industry median of 15.95. Astellas Pharma's overall GF Score™ is 73/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EV-to-EBIT calculated?
EV-to-EBIT is calculated from a company's financial statements. For Astellas Pharma (ALPMF), the current EV-to-EBIT is 10.02 as of Jul. 22, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Astellas Pharma (ALPMF) Overvalued in 2026?
Based on GuruFocus' analysis, Astellas Pharma stock appears to be undervalued.
The current stock price of $12.85 is trading 9.4% below its estimated GF Value™ of $14.19.
GuruFocus considers Astellas Pharma to be Fairly Valued.
Key valuation signals for ALPMF:
EV-to-EBIT: 10.02 (30% below median its 10-year median of 14.39)
GF Value™: $14.19 vs. price of $12.85 (9.4% below fair value)
Industry Position: 37.2% below the Drug Manufacturers median (#222 of 689)
No single metric tells the full story. See the ALPMF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Astellas Pharma Inc is a specialty international pharmaceutical company. The company focuses on accelerating the discovery, development, and commercialization of ground-breaking innovations that could redefine expectations of care for difficult-to-treat diseases. The group is committed to driving innovation in immuno-oncology, gene therapy, mitochondria, blindness and regeneration, and targeted protein degradation. Its core products include anticancer agents like XTANDI, XOSPATA, and PADCEV; VEOZAH for the treatment of vasomotor symptoms due to menopause; Betanis / Myrbetriq / BETMIGA for the treatment of overactive bladder (OAB); and Prograf, an immunosuppressant for organ transplantation.
73GF Score
Get the complete analysis for ALPMF
EV-to-EBIT is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
ALPMF has been successfully added to your 
